Galena Biopharma, Inc.
Period: Aug 11, 2014 to Jan 31, 2017
Lead Plaintiff Deadline: Apr 14, 2017
Summary of Case:
A securities class action has been filed against Galena Biopharma, Inc. ("Galena") on behalf of all persons and entities who purchased or otherwise acquired Galena publicly traded securities between August 11, 2014 through January 31, 2017. This case has been filed in the USDC - New Jersey.
The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Galena's sales of their first commercial product, Abstral, were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) as a result, Defendants' statements about Galena's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you purchased this company's shares during the Class Period and suffered a loss or for further information about the case, please review the links below.